8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): July 13, 2010 (July 12, 2010)

Commission File Number: 0-24260

Amedisys, Inc.

(Exact Name of Registrant as specified in its Charter)

Delaware	11-3131700
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

5959 S. Sherwood Forest Blvd., Baton Rouge, LA 70816

(Address of principal executive offices, including zip code)

(225) 292-2031 or (800) 467-2662

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Section 7 - Regulation FD

Item 7.01. Regulation FD Disclosure.

On July 12, 2010, Amedisys, Inc. (“we,” “us,” “our” or the “Company”) issued a press released titled “Amedisys Hosting Investor Update Conference Call.” A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

The information presented in Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, unless we specifically state that the information is to be considered “filed” under the Exchange Act or specifically incorporate it by reference in any filing under the Securities Exchange Act of 1933, as amended, or the Exchange Act.

Section 9 - Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

99.1 Press Release dated July 12, 2010 titled “Amedisys Hosting Investor Update Conference Call” (furnished only)

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AMEDISYS, INC.
By:	/s/ Dale E. Redman
	Dale E. Redman
	Chief Financial Officer and Duly Authorized Officer
DATE:	July 13, 2010

Exhibit Index

Exhibit No.	Description
99.1	Press Release dated July 12, 2010, titled “Amedisys Hosting Investor Update Conference Call” (furnished only)

EX-99.1

Exhibit 99.1

Amedisys Hosting Investor Update Conference Call

BATON ROUGE, Louisiana (July 12, 2010) - Amedisys, Inc. (NASDAQ: “AMED”), one of America’s leading home health and hospice nursing companies, today announced that we will host a conference call with the investment community on Tuesday, July 13, 2010 at 9:00 a.m. ET to discuss preliminary results for the second quarter of 2010 and update the market on the status of the Senate Finance Committee inquiry and Securities and Exchange Commission investigation.

We currently believe that our second quarter net income will be approximately $1.12 per share. These results include nonrecurring costs of 17 cents per share primarily associated with realignment of operations, and the Senate Finance Committee and SEC investigations; $3.5 million or 7 cents per share we received from CMS under their pay for performance demonstration program and a reversal of the first quarter corporate bonus accrual which amounted to 7 cents per share. The net effect of these items on reported earnings per share was a reduction of approximately 3 cents per share.

To participate in the conference call, please dial 800-723-6604 (Toll free) or 785-830-7977 (Toll) a few minutes before 9:00 a.m. ET. A replay of the conference call will be available through July 20, 2010. The replay dial in number is 888-203-1112 (Toll free) or 719-457-0820 (Toll). The replay pin number is 3314234.

The call will also be available through our website on our Investor Relations page at the following web address:

http://www.amedisys.com/investors

Amedisys, Inc. (the “Company”) is headquartered in Baton Rouge, Louisiana. Our common stock trades on the NASDAQ Global Select Market under the symbol “AMED”.

This press release includes statements that may constitute “forward-looking” statements, usually containing the words “believe”, “estimate”, “project”, “expect”, “anticipate” or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Many of the factors that could cause or contribute to such differences are described in the Company’s periodic reports and registrations statements filed with the Securities and Exchange Commission, and include, but are not limited to the following: general economic and business conditions, changes in or failure to comply with existing regulations or the inability to comply with new government regulations on a timely basis, changes in Medicare and other medical reimbursement levels, ability to complete acquisitions announced from time to time, and any financing related thereto, the ability to meet debt service requirements and to comply with covenants in debt agreements, adverse changes in federal and state laws relating to the health care industry, demographic changes, availability and terms of capital, ability to attract and retain qualified personnel, ongoing development and success of new start-ups, ability to successfully integrate newly acquired agencies, changes in estimates and judgments associated with critical accounting policies, business disruption due to natural disasters or acts of terrorism, changes in or developments with respect to any litigation or investigation relating to the Company, including the Senate Finance Committee inquiry and the Securities and Exchange Commission investigation, and various other matters, many of which are beyond management’s control. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.

Our company website address is www.amedisys.com. We use our website as a channel of distribution for important company information. Important information, including press releases, analyst presentations and financial information regarding our Company is routinely posted on and accessible on the Investor Relations subpage of our website, which is accessible by clicking on the tab labeled “Investors” on our website home page. We also use our website to expedite public access to time-critical information regarding our Company in advance of or in lieu of distributing a press release or a filing with the Securities and Exchange Commission (“SEC”) disclosing the same information. Therefore, investors should look to the Investor Relations subpage of our website for important and time-critical information. Visitors to our website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations subpage of our website. In addition, we make available on the Investor Relations subpage of our website (under the link “SEC filings”) free of charge our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, ownership reports on Forms 3, 4 and 5 and any amendments to those reports as soon as practicable after we electronically file such reports with the SEC. Further, copies of our Certificate of Incorporation and Bylaws, our Code of Ethical Business Conduct and the charters for the Audit, Compensation and Nominating and Governance Committees of our Board are also available on the Investor Relations subpage of our website (under the link “Corporate Governance”).

Contact:	For Investors:	For Media:
	Amedisys, Inc.	Amedisys, Inc.
	Director of Investor Relations	Senior Vice President Marketing & Communications
	Kevin B. LeBlanc	Jacqueline Chen Valencia
	225.298.6391	225.295.9688
	kleblanc@amedisys.com	jacqueline.chen@amedisys.com

###